Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.69 |
| ▸ | CDK1 | P06493 | 19/20 | 0.69 |
| ▸ | CDK2 | P24941 | 19/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776403 | 1.00 | KDR (0.69) | KDRCDK1CDK2CA2CCNB1 | |
| SCHEMBL2934293 | 1.00 | KDR (0.69) | KDRCDK1CDK2CA2CCNB1 | |
| SCHEMBL2939510 | 0.92 | KDR (0.66) | KDRCDK1CDK2CA2CCNB1 | |
| SCHEMBL1773743 | 0.92 | KDR (0.66) | KDRCDK1CDK2CA2CCNB1 | |
| SCHEMBL1773742 | 0.92 | KDR (0.66) | KDRCDK1CDK2CA2CCNB1 | |
| SCHEMBL1776255 | 0.91 | KDR (0.67) | KDRCDK1CDK2CA2CCNB1 | |
| SCHEMBL2937047 | 0.91 | KDR (0.67) | KDRCDK1CDK2CA2CCNB1 | |
| SCHEMBL1776257 | 0.91 | KDR (0.67) | KDRCDK1CDK2CA2CCNB1 | |
| SCHEMBL2941710 | 0.90 | KDR (0.64) | KDRCDK1CDK2CA2CCNB1 | |
| SCHEMBL1774763 | 0.90 | KDR (0.64) | KDRCDK1CDK2CA2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943629-B2 | Anticancer/antitumor agents; S-(4-([4-([(1R,2R)-2-Hydroxy-1-methylpropyl]amino)-5-(trifluoromethyl)-pyrimidin-2-yl]amino)phenyl)-S-methyl-N-[(trifluoromethyl)sulphonyl]-sulphimide for example | BAYER SCHERING PHARMA AG (DE) | 2011-05-17 | — | — | US | disclosed |
| EP-2029552-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | Bayer Schering Pharma AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007140957-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | PRKCE, BRAF, PACSIN2 | KDR 1439/4885CDK1 160/4885CDK2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.